Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate
Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate
Lumos Pharma 2023年第四季度GAAP每股收益（1.170 美元）未達到預期（1.150 美元），銷售額爲826.000萬美元，超過17.5萬美元的預期
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.150) by 1.74 percent. The company reported quarterly sales of $826.000 thousand which beat the analyst consensus estimate of $1.750 thousand by 47.10K percent. This is a 61.33 percent increase over sales of $512.000 thousand the same period last year.
Lumos Pharma（納斯達克股票代碼：LUMO）公佈的季度虧損爲每股1.170美元，比分析師普遍預期的1.150美元（1.150美元）低1.74％。該公司公佈的季度銷售額爲82.6萬美元，比分析師普遍預期的1750美元高出47.1萬個百分點。與去年同期的51.2萬美元銷售額相比，增長了61.33％。